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Introduction
Myelodysplastic syndromes (MDS) are chronic bone marrow (BM) disorders char-
acterized by peripheral blood cytopenias, predominantly in older persons with an
average age at diagnosis of 75 years.1,2 The natural history of MDS is heterogeneous,
ranging from indolent conditions to forms similar to acute myeloid leukemia (AML).
In 1997, an International Prognostic Scoring System (IPSS) was established based on
the percentage of BM blasts, number of cytopenias and cytogenetic characteristics.3
In 2012, this prognostic scoring system was refined (IPSS-R) to include better catego-
rization of cytopenias, blast cell percentage and an improved risk stratification of the
cytogenetic risk groups.4 Generally, MDS are divided into two prognostic groups:
lower-risk MDS (LR-MDS) with patients from the (very) low risk or intermediate risk
groups, and higher-risk MDS (HR-MDS) with patients from the (very) poor risk
groups, as defined within the IPSS-R.2
The majority of patients with MDS (75%) have LR-MDS, which was the focus of
the European LeukemiaNet MDS (EUMDS) Registry until 2017. The EUMDS
Registry is a pragmatic, observational study, which has collected prospectively longi-
tudinal data from more than 2,738 patients with MDS,
including 2,498 LR-MDS patients with a median age of 75
years, and a follow-up of up to 11 years, in 16 European
countries plus Israel from 148 active sites (progress report as
of March 1st 2020). Progression to HR-MDS/AML has
occurred in 314 LR-MDS patients (13%), and 910 patients
(33%) had died at time of last report. Data quality control,
including monitoring of both clinical performance and data
collection, has been implemented since the initiation of the
EUMDS Registry. New prognostic indicators in LR-MDS
have been identified as part of the MDS-RIGHT project
(https://mds-europe.eu/right) funded by Horizon 2020, which
started in May 2015 with an overarching aim of defining
and implementing more (cost)-effective and safer interven-
tions in LR-MDS.
Symptoms of anemia, the most common cytopenia in
LR-MDS, accompanied by infectious or bleeding complica-
tions predominate in LR-MDS.5 About 25% of these
patients develop AML, but most patients die from compli-
cations related to progressive BM failure and worsening
cytopenias, and from their negative interaction with the
extra-hematologic comorbidities presented by those
patients of advanced age.6,7 Patients with LR-MDS are char-
acterized by a notable reduction in health related quality of
life (HRQoL).8,9 Moderate to severe anemia in older individ-
uals (>60 years) leads to increased mortality both in patients
with LR-MDS and in the general population.10,11 Likewise,
anemia represents an unfavorable prognosticator in possi-
ble pre-MDS conditions at advanced age.12 Improving
response prediction will contribute to more effective and
targeted use of the available health care interventions
(HCI).13
According to the available evidence- and consensus-
based therapeutic guidelines, current therapeutic interven-
tions in LR-MDS include red blood cell transfusion (RBCT),
erythropoietin stimulating agents (ESA), lenalidomide, and
iron chelation therapy (ICT).11 For ESA, a predictive model
has identified a group of patients characterized by serum
erythropoietin (EPO) levels <500 mU/mL and a transfusion
need of <2 units RBC/month with a favorable response
compared to patients with higher EPO levels and/or higher
numbers of RBCT/month.14 Treatment with lenalidomide is
only recommended for a small subgroup of patients with
partial loss of chromosome 5 (5q-) and RBCT-dependent
anemia.15,16
The most frequently applied outcome parameter in this
LR-MDS patient population is overall survival (OS).
Analysis of the EUMDS Registry data showed that the cur-
rently available risk scoring systems, including the IPSS-R,
have a better prognostic capacity for disease progression to
AML as compared with OS.2 We estimated that 58% of
deaths in this population are not related to disease progres-
sion, but are attributable to non-leukemic death.2,17 A high
proportion of patients with LR-MDS have a median sur-
vival of up to 5-10 years, meaning that clinical trials, the
design of which identifies survival as a primary endpoint,
may result in a potentially biased assessment of the effec-
tiveness and evidence on the appropriate use of the avail-
able interventions. Therefore, we have explored additional
relevant outcome parameters in a Delphi survey, which
could be used to circumvent the limited value of survival as
primary endpoint in LR-MDS.18 
Additional evidence is required to extend the existing
prognostic and therapeutic response indicators in the older
LR-MDS population, and to identify meaningful biological
and clinical endpoints, including patient-reported outcome
measures and other patient-related factors. These new end-
points may provide information on the effectiveness of the
available therapeutic interventions early in the natural his-
tory of the disease. These early indicators of treatment
response may drive a more effective use of those interven-
tions currently made.
Recent studies conducted on the large population of
patients with LR-MDS included in the EUMDS Registry
during its first 10 years of activity allowed validation of
RBCT requirement and HRQoL as independent and mean-
ingful outcome indicators and reliable measures of response
to interventions, supporting their integration in the MDS-
Core Outcome Set (COS) in this patient population.18 In
addition, prospective studies based on the unbiased dataset
of the EUMDS Registry allowed identification of early
response determinants for targeted use of treatment modal-
ities, including ESA, lenalidomide, and ICT.
Novel outcome indicators and meaningful early
clinical endpoints in patients with lower-risk
myelodysplastic syndromes
Kinetics of blood counts decrease is an independent
outcome indicator in lower-risk myelodysplastic syn-
dromes
The prognosis of LR-MDS is heterogeneous.2 Early iden-
tification of patients at risk of rapid progression should rely
on universal, affordable and non-invasive tools to gain
acceptance in an older population often managed in com-
munity care centers. All current MDS prognostic scores rely
on steady-state assessments of cytopenias, i.e., hemoglobin
(Hb)-levels, neutrophil or platelet counts on the day of ini-
tial assessment.19 Time-dependent prognostic scores require
repeated BM examinations, raising acceptability issues in
this older patient population. To circumvent this limitation,
we analyzed the prognostic role of the kinetics of cytope-
nias during the first visit interval (6 months) following diag-
nosis in LR-MDS patients prospectively included in the
EUMDS registry.20 We performed a landmark analysis at the
second visit, at around 6 months from diagnosis, to apply
simple prognostic criteria in general clinical practice.
The results showed that a relative drop in platelets >25%
at the 6-month landmark predicted shorter 5-year OS; 22%
versus 49% in patients with platelet drop ≤ 25% (P<10-4),
regardless of baseline IPSS-R or absolute platelet counts.
Conversely, relative neutrophil drop >25% had no signifi-
cant impact on OS. Subsequently, a classifier was built
based on RBCT-dependency and relative platelet drop
>25% at landmark. Patients with none (62%), either one of
the two criteria (27%) or both criteria (11%) had 5-year OS
of 53.3%, 32.7% and 9.0%, respectively (P<10-4) (Figure 1).
Sensitivity analyses confirmed the applicability of this sim-
ple classifier even when follow-up visits were planned at
any time during the first ten months after diagnosis, thus
capturing most situations encountered in daily practice.20
Red blood cell transfusion requirement is an independ-
ent outcome indicator and freedom from transfusion a
meaningful clinical endpoint in patients with lower-risk
myelodysplastic syndromes
In order to extend existing outcome parameters in the
older LR-MDS population,21 RBCT administration in the
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LR-MDS patients enrolled in the EUMDS Registry was
evaluated with the aim of estimating the prognostic impact
of regular RBCT and to validate RBCT-free survival as an
early clinical endpoint in this patient population. The refer-
ence endpoint was progression-free survival (PFS), because
both progression and death indicate the end of a relatively
stable phase of LR-MDS.
A cohort of 1,267 patients with all relevant data available
was included in this analysis. The patients were subdivided
for the landmark analysis into four groups: no transfusions,
>0 to <0.75 units/month (low transfusion dose), 0.75-1.75
units/month (mid transfusion dose) and >1.75 units/month
(high transfusion dose). The greatest effect, compared to
the non-transfused patients, occurred in patients receiving
transfusions at low dose densities, since the impaired out-
come of the mid and high transfusion density group was
similar (Figure 2). In multivariable analysis, RBCT dose den-
sity retained statistical significance at P<10-4.
Since treatment with ESA, lenalidomide and iron chela-
tors may improve erythropoiesis and reduce the need for
RBCT, these variables were included in the regression
model. This analysis resulted in an effect for the dose den-
sity similar to the previous analyses at P<10-4.21 However,
the dose density effect continues to increase beyond one
unit per month after correction for the three interventions
(ESA, iron chelation and lenalidomide) up until a dose of six
units per month (Figure 3). The relative log ratios on PFS of
this analysis clearly showed that the deleterious effect of
transfusions already occurred at a very low transfusion bur-
den (<3 units per 16 weeks as defined in the revised
International Working Group, IWG) report, confirming the
outcome of the landmark analysis (see above). It is impor-
tant to realize that patients with a transfusion dose of 1-2
units per 16 weeks are considered to be untransfused in the
recently revised IWG report, but are recommended to be
studied in future clinical trials.21
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Figure 1. Kaplan-Meier plots of overall survival from land-
mark according to the 6-month European LeukemiaNet
MDS (EUMDS) classifier based on platelet drop >25% and
red blood cell transfusion (RBCT)-dependency at landmark.
Black: no criteria (no platelet drop >25% or RBCT-dependen-
cy at landmark); red: either one of the two criteria; green:
both criteria.
Figure 2. Kaplan-Meier plots of progression-
free survival (PFS) according to  transfusion
status at the landmark of visit 3 (1 year
after registration). Kaplan -Meier plot of PFS
of patients receiving no transfusions (red
line) or transfusions at a  low dose density:
from >0 to <0.75 units per month (green
line); mid dose density:  0.75-1.75 units per
month (purple line); high dose density >1.75
units per month  (blue line).
Relevance of patient-reported outcomes in lower-risk
myelodysplastic syndromes 
Health related quality of life is an important patient-
reported outcome (PRO). It provides specific information
on older patients with chronic diseases that might not be
reflected in the level of physical activity and relevant labo-
ratory parameters, including Hb levels.22 Preliminary data in
HR-MDS patients suggest that these limitations may pre-
dict an unfavorable clinical outcome.8 However, definitive
data on HRQoL in LR-MDS are rare. This EUMDS Registry
project investigated the HRQoL-profile of LR-MDS patients
at time of diagnosis as compared with age- and sex-
matched reference groups from the general population.23
HRQoL was measured by the EuroQol-5 dimension (EQ-
5D) score at the time of study enrolment.24,25 Population
norms were used to assess the relative HRQoL of patients
in comparison to those of the average person in the com-
munity.26
A significant proportion of MDS patients reported mod-
erate or severe problems in the dimensions pain/discomfort
(50%), mobility (41%), anxiety/depression (38%), and
usual activities (36%). Clinically meaningful restrictions in
the EQ-5D index, EQ-Visual Analog Scale (VAS) were
observed significantly more often in older patients and in
those with a high co-morbidity burden, low Hb levels or
RBCT need (P<10-3). Relative to the EQ-5D index and EQ-
VAS scores in the reference group, HRQoL was significantly
lower for groups of patients with MDS who were older,
female, or had increased comorbidities, low Hb-levels or
RBCT dependence.23
Restrictions in distinct dimensions of the EQ-5D were
also observed when compared with European reference
populations, but this effect might (partly) be explained by
the anemia in the MDS cohort, since older anemic patients
in the general population also have a decreased HRQoL.11
Low Hb levels and RBCT need were associated both with
a decreased EQ-5D index and a decreased EQ-VAS after
adjustment for co-variables in this EUMDS-Registry study,
further supporting the use of RBCT requirement as an indi-
cator of loss of effectiveness of interventions and worsening
outcome. In addition, transfusion-free survival appeared to
be a meaningful clinical endpoint in patients with lower-
risk MDS, as shown in the transfusion study.21 These find-
ings have important implications for every-day clinical
practice and the design of clinical endpoints. 
Novel treatment-response indicators in lower
risk myelodysplastic syndromes 
Early initiation of treatment with erythropoietin stimulat-
ing agents is an important response indicator and signif-
icantly delays the onset of red blood cell transfusion
dependency in patients with lower-risk myelodysplastic
syndromes
Anemia of patients with LR-MDS and RBCT dependency
have been associated with reduced HRQoL in several
prospective trials27,28 and with reduced survival in retrospec-
tive registry reports.10 Current guidelines recommend ESA
as first-line treatment for LR-MDS patients with sympto-
matic anemia.13 In recent studies, overall response rates var-
ied between 38% and 66%, with a median response dura-
tion of around 20 months.29 Retrospective analyses of large
multi-center cohorts from different countries compared sur-
vival in patients treated with ESA within clinical studies
with untreated patients. Survival was markedly better in
the group exposed to ESA with no difference in AML trans-
formation.30,31
Within the EUMDS registry, the effects of ESA treatment
on outcomes were explored amongst 1,696 unselected
patients with anemia.32 To overcome potential confounding
by non-random allocation of ESA treatment, proportional
hazards regression models comparing time-to-event out-
comes in treated and untreated patients were weighted by
stabilized inverse probability of treatment weights based
on the propensity of a patient to receive ESA treatment.
Only patients with comparable propensity scores were
included in the analyses to estimate the effects of ESA treat-
ment on outcomes. The relationship between the effects of
ESA and pre-ESA treatment transfusion status was explored
Novel dynamic outcome indicators and clinical endpoints in MDS
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Figure 3. Influence of dose
density on progression-free
survival (PFS) in a multivariate
regression model adjusted for
treatment with either erythro-
poiesis-stimulating agent, iron
chelation or lenalidomide.
Dose density: average number
of transfusions per month, cal-
culated from start of transfu-
sion until date of analysis.
using this model. A non-significant beneficial effect of ESA
treatment on OS was estimated from the weighted regres-
sion model comparing patients with comparable propensi-
ty scores (hazard ratio [HR] 0.82, 95% confidence interval
[CI]: 0.65-1.04; P=0.09). A non-significant estimate of a ben-
eficial effect of ESA treatment on progression to AML or
high-risk MDS was observed (HR 0.88, CI: 0.63-1.22;
P=0.44). Exploration of the relationship between ESA treat-
ment and pre-treatment transfusion status revealed a larger
estimated effect of ESA on survival amongst patients who
had not received RBCT prior to starting ESA treatment (HR
0.71, 95%CI: 0.49-1.03; P=0.07) than amongst patients who
had received prior RBCT (HR 0.93, 95%CI: 0.70-1.26;
P=0.67). 
Responding patients had a better prognosis, in terms of a
lower risk for death (HR 0.65, 95%CI: 0.45-0.893; P=0.018).
The effect of response on time to first post-ESA treatment
transfusion was significant after stratification by pre-treat-
ment transfusion experience. Importantly, and irrespective
of response status, patients who received RBCT before
starting ESA had a shorter time to their first post-treatment
transfusion (median 6.1 vs. 23.3 months for non-transfused
patients; HR 2.4, 95%CI: 1.75-3.31; P<10-4).
This large observational study showed that the response
rate to ESA, as well as the capacity of these agents to signif-
icantly delay the onset of a regular RBCT need, is most pro-
nounced in RBCT-naïve patients, suggesting that RBCT-
naïve patients are more responsive. These results identify
early initiation of ESA treatment as a relevant treatment
response indicator, and suggest that ESA should be recom-
mended as first-line treatment in LR-MDS patients with
symptomatic anemia before starting regular RBCT. 
Labile plasma iron levels and non-transferrin bound iron
are early and clinically relevant indicators of iron toxicity
and impact of iron chelation therapy on outcome in
patients with lower-risk myelodysplastic syndromes
receiving red blood cell transfusion
The majority of LR-MDS patients become RBCT
dependent over time. With an expected survival of up to 12
years, these patients are prone to long-term accumulation
of iron due to RBCT.33 Iron overload may also occur in a
fraction of MDS patients who do not receive RBCT, result-
ing from the stimulation of intestinal iron absorption, medi-
ated through suppression of hepcidin production by inef-
fective erythropoiesis.34 The toxic effects of iron overload in
other iron loading diseases are well known, but the conse-
quences in MDS remain to be elucidated. To this end, we
evaluated erythroid marrow activity, hepcidin levels, and
body iron status, including non-transferrin bound iron
(NTBI) and labile plasma iron (LPI) levels over time in LR-
MDS patients and their relation with disease subtype and
RBCT history within the EUMDS Registry.35
Detectable NTBI already occurred in all patient groups at
registration, with highest levels in patients with MDS and
ring sideroblasts (MDS-RS). The median LPI levels were
below the level of detection in all patient groups at registra-
tion, except in transfusion dependent (TD) MDS-RS
patients.35 Hepcidin levels increased with the number of
transfused units, but in contrast, hepcidin levels significant-
ly decreased over time in transfusion independent (TI)
MDS-RS patients. Serum transferrin (sTfR) levels increased
significantly over time in both TI and TD MDS-RS patients
(P-values from 0.01 to <10-3). Both elevated NTBI and LPI
levels showed a threshold effect with transferrin saturation
(TSAT) rates of >70% and >80%, respectively. Elevated LPI
levels occurred almost exclusively in patients with MDS-RS
and/or patients, who had received RBCT. Once LPI levels
are increased, survival time decreases, with greatest impact
in patients who are TD (adjusted HR, 4.03, 95%CI: 0.95-
17.06; P=0.06). 
This study among LR-MDS patients showed that both
treatment with RBCT and presence of ring sideroblasts
increased the occurrence of the toxic iron species NTBI and
LPI in serum. These data suggest that body iron accumula-
tion and toxic iron species (NTBI and LPI) occur mainly in
MDS-RS patients along the axis of ineffective erythro-
poiesis, characterized by elevated sTfR, low hepcidin, and
increased iron levels, in some MDS subtypes, irrespective of
receiving RBCT. Transfusional parenchymal iron overload,
reflected by the combination of high serum ferritin levels,
as well as direct iron toxicity, reflected by the presence of
NTBI and LPI, was noted more frequently in MDS patients
with ring sideroblasts compared to patients without ring
sideroblasts. These data show that elevated LPI levels were
associated with decreased survival both in the overall pop-
ulation of this study and in the patient groups subdivided
by RBCT status. This implies that the widely used param-
eter TSAT cannot serve as a parameter to predict survival;
however, TSAT rates can be used as a pre-screening marker
to identify patients who are at risk of developing elevated
LPI levels and associated poor prognosis. Finally, we could
demonstrate in a limited number of patients treated with
iron chelators that LPI levels decreased below detectable
levels. This study suggested that NTBI and LPI may serve as
early indicators of iron toxicity and as a measure for the
effectiveness of iron chelation therapy in patients with
lower risk MDS. 
Iron overload due to RBCT is associated with increased
morbidity and mortality in patients with LR-MDS.36 Several
studies have reported beneficial effects of ICT on survival
and other clinical outcomes in MDS patients with iron over-
load.37,38 However, valid data on the effect of ICT are limited
since most studies are executed in small, selected patient
groups or suffer from serious methodological problems
such as confounding by indication.38 Performing a random-
ized, controlled trial (RCT) for this research question is
awkward, and patients included in RCT may not reflect the
general LR-MDS patients, who are usually patients of
advanced age with multiple chronic, complex comorbidi-
ties. In addition to the possible beneficial effects of ICT on
survival, increasing evidence indicates hematologic
improvement in patients during ICT.39 Following improve-
ment in cytopenias, transfusion independency is achieved
in a minority of chelated patients.40,41
Results from a study conducted within the EUMDS reg-
istry on 490 non-chelated and 199 chelated patients using
ICT as a time-dependent variable showed that the hazard
ratio for OS was 0.50 (95%CI: 0.34-0.74) after adjusting for
relevant confounding factors. Restriction of the analysis to
150 patients who were initially treated with deferasirox
resulted in the adjusted HR for OS of 0.38 (95%CI: 0.24-
0.60), while patients who were initially treated with defer-
oxamine had  inferior OS compared to deferasirox treated
patients (adjusted HR: 2.46, 95%CI: 1.12-5.41). The
propensity-score analysis matching for all relevant vari-
ables, and a multivariate Cox proportional hazard model
restricted to the deferasirox treated patients resulted in the
adjusted HR for OS of 0.34 (95%CI: 0.22-0.53). An ery-
throid response occurred in 77 chelated patients: 61 patients
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had a reduction in transfusion density, and 16 patients who
did not have a reduction in transfusion density became
transfusion independent during at least one visit interval. 
The TELESTO trial42 is the only prospective, randomized,
placebo-controlled study of ICT in MDS patients compar-
ing deferasirox with a placebo-control group. This study
evaluated the event-free survival (EFS) (a composite out-
come, including non-fatal events related to cardiac and liver
function, and transformation to AML or death) and safety
of deferasirox versus placebo in low and intermediate-1-risk
MDS patients. This trial demonstrated an EFS risk reduc-
tion of 36.4% in the deferasirox arm (P=0.015), but the
median OS in the deferasirox-treated arm did not differ (HR
0.83, 95%CI: 0.54-1.28; P=0.200) when compared with
placebo. The results of the TELESTO study are in line with
the EUMDS study, but the patients included may not rep-
resent ‘real life’ older MDS patients with multiple comor-
bidities, as reflected by the mean age of 61 years of the
patients included in TELESTO study compared to the mean
age of 70 years of the chelated patients in the EUMDS
Registry study. Furthermore, low accrual rates and the
cross-over to ICT after cessation of the placebo affected the
statistical power of the TELESTO study.
Summary and concluding remarks
Available evidence suggests that in most patients with
LR-MDS the risk of death is not related to disease progres-
sion but is mainly attributable to non-leukemic death.2,17 In
addition, a proportion of these patients have prolonged sur-
vival that precludes the design of clinical trials adopting OS
as a primary endpoint. These challenges have resulted in
potentially biased assessment of the effectiveness and
appropriate use of the available interventions in this patient
population. The EUMDS Registry has identified novel
meaningful outcome indicators and clinical endpoints, and
reliable measures of response to HCI (Figure 4).
The results of our analysis indicate that RBCT density is
strongly associated with a decreased OS, even at relatively
low dose densities. In addition, we observed that an early
decrease in platelet count is an independent adverse prog-
nostic indicator in LR-MDS, and combining relative platelet
drop and transfusion dependency allows early identifica-
tion of patients at risk of rapid progression, and may guide
early therapeutic interventions, including allogeneic
hematopoietic stem cell transplantation or experimental
interventions. Taken together, these results indicate that
regular RBCT requirement, early platelet count kinetics,
and restriction in HRQoL are early independent and mean-
ingful outcome indicators, and reliable measures of effec-
tiveness of therapeutic interventions, evaluated in this set of
studies. These findings support the integration of RBCT
requirement and HRQoL in the general core outcome sets
and in response criteria in patients with LR-MDS, and have
important implications for clinical practice and the design of
clinical endpoints. Our results strongly support the adop-
tion of freedom from transfusion as a meaningful clinical
endpoint in patients with LR-MDS.
Anemia is the main determinant of therapeutic interven-
tion in patients with LR-MDS, and ESA are recommended
as first-line treatment for patients with symptomatic ane-
mia.10 The observational studies within the EUMDS
Registry showed that the response rate, as well as the
capacity of these agents to delay the onset of a regular
RBCT need, is most pronounced in RBCT-naïve patients.
These results identified early initiation of treatment with
ESA as a major treatment response indicator, and indicate
that ESA should be recommended in LR-MDS patients
with symptomatic anemia before starting regular RBCT.
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Figure 4. Overview of novel out-
come indicators and clinical end-
points identified  in the European
LeukemiaNet myelodysplastic
syndromes (EUMDS) Registry.
ESA: erythropoietin stimulating
agents; LPI: labile plasma iron;
NTBI: non-transferrin bound iron;
TSAT: transferrin saturation;
HRQoL: health  related quality of
life.
After the onset of RBCT dependency, patients with LR-
MDS are prone to long-term accumulation of iron.1,43 The
EUMDS Registry studies provided evidence that elevated
LPI levels are associated with reduced survival in RBCT
dependent patients, whereas iron chelation therapy nor-
malizes LPI levels. These findings suggest that NTBI and
LPI may serve as early indicators of iron toxicity and a
means to measure the effectiveness of iron chelation ther-
apy in patients with LR-MDS. However, qualified NTBI
and LPI are only currently available in specialized labora-
tories.44
Large observational cohorts with detailed clinical and
laboratory data, like the EUMDS cohort, are the ideal
framework in which to identify well defined MDS sub-
types that may benefit from novel targeted treatments. An
example of such a subtype is MDS with loss of parts of
chromosome 5, namely del5q; these patients have a rela-
tively favorable outcome on lenalidomide treatment. In
order to identify homogeneous subsets of patients within
MDS, preliminary evidence has suggested that recently
identified mutations in splicing factors may recognize dis-
tinct disease entities within myeloid neoplasms.45 Splicing
modulators are now in pre-clinical testing, and are very
likely to lead to the introduction of effective drugs for spe-
cific groups of MDS patients. Luspatercept, a specific
inhibitor of growth and differentiation factor-11, a mem-
ber of the transforming growth factor β superfamily,
induced substantial improvement of anemia, especially in
patients with ring sideroblasts.46 Characterization of indi-
vidual cases by new genetic markers (one of the main
objectives of the MDS-RIGHT project) will allow refined
classification of patients into biological subgroups that are
expected to respond differently to therapeutic interven-
tions to guide discontinuation of those interventions that
are less effective or less cost-effective.
The main question is whether RCT data and retrospec-
tive cohort data in selected tertiary care centers are repre-
sentative of the 'real world' data of the older patients with
LR-MDS in the general population. A careful comparison of
the 'real world' data and the RCT data will be needed in
order to provide a clear answer to these questions.
Meanwhile, the current analyses of data collected over 10
years in the EUMDS Registry provides relevant and impor-
tant information which could help assess prognosis and
response to standard interventions in this older patient
group.
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